{"organizations": [], "uuid": "12f8f5806a225c6953137cdb01998ab51831451b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180130.html", "section_title": "Archive News &amp; Video for Tuesday, 30 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-celon-pharma-signs-deal-for-indust/brief-celon-pharma-signs-deal-for-industrial-development-and-production-for-clinical-trial-of-anti-vegf-protein-idUSFWN1PP0EM", "country": "US", "domain_rank": 408, "title": "BRIEF-Celon Pharma Signs Deal For Industrial Development And Production For Clinical Trial Of Anti-VEGF Protein", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.414, "site_type": "news", "published": "2018-01-30T15:38:00.000+02:00", "replies_count": 0, "uuid": "12f8f5806a225c6953137cdb01998ab51831451b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-celon-pharma-signs-deal-for-indust/brief-celon-pharma-signs-deal-for-industrial-development-and-production-for-clinical-trial-of-anti-vegf-protein-idUSFWN1PP0EM", "ord_in_thread": 0, "title": "BRIEF-Celon Pharma Signs Deal For Industrial Development And Production For Clinical Trial Of Anti-VEGF Protein", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "celon pharma sa", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 30 (Reuters) - Celon Pharma SA:\n* SIGNS CONTRACT WITH BIOTECHPHARMA FOR INDUSTRIAL DEVELOPMENT AND PRODUCTION FOR CLINICAL TRIAL IN GMP QUALITY OF ANTI-VEGF PROTEIN\n* VALUE OF CONTRACT WITH BIOTECHPHARMA IS ABOUT 2-3 MILLION EUROS Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-30T15:38:00.000+02:00", "crawled": "2018-01-31T16:25:56.054+02:00", "highlightTitle": ""}